Phase 1
Completed N=28
A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults
Healthy Volunteers
Source: ClinicalTrials.gov NCT05064449 ↗
Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcomePrimary: Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole — 1310; 1527 nanogram per milliliter (ng/mL)
Summary
The main aim of this study is to check how itraconazole and mefenamic acid affect the way soticlestat is processed by the body.
The study will have 2 parts. Participants can only participate in one study part.
Part 1: Participants will check into the study clinic to receive soticlestat, four days later they will begin receiving itraconazole and will stay in the clinic for 11 more days, receiving soticlestat in combination with itraconazole on one of those days. Participants will be contacted about 8 days after leaving the clinic for follow-up.
Part 2: Participants will check into the study clinic to receive soticlestat, four days later they will begin receiving mefenamic acid and will stay in the clinic for 7 more days, receiving soticlestat in combination with mefenamic acid on one of those days.. Participants will be contacted about 9 days after leaving the clinic for follow-up.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole |
1310; 1527 | — |
| PRIMARY Part 2, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Mefenamic Acid |
1414; 1517 | — |
| PRIMARY Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Itraconazole |
1483; 1914 | — |
| PRIMARY Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Mefenamic Acid |
1533; 1594 | — |
| PRIMARY Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Itraconazole |
1391; 1697 | — |
| PRIMARY Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Mefenamic Acid |
1423; 1528 | — |
| PRIMARY Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Itraconazole |
0.500; 0.503 | =0.2305 |
| PRIMARY Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Mefenamic Acid |
0.505; 0.522 | =0.5830 |
| SECONDARY Parts 1 and 2: Number of Participants Reported One or More Treatment-emergent Adverse Event (TEAE) |
1; 2; 3; 1; 0; 3 | — |
| SECONDARY Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Laboratory Evaluations |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Vital Signs |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG) |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Parts 1 and 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) |
0; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Has body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to ( =90/40 millimeter of mercury (mmHg) and =45 beats per minute (bpm) and =80 milliliter per minute (mL/min) at screening;
- Liver function tests including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <=1.5*the upper limit of normal (ULN) at screening and check-in.
- Able to swallow multiple tablets.
Exclusion Criteria
- Has history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participants by their participation in the study.
- Has history or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
- Has history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
- Unable to refrain from or anticipates the use of:
- Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first dosing.
- Has history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer 354 milliliter (mL)/12 Ounce [oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).
- Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
- Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.
- Donation of blood or significant blood loss within 56 days prior to the first dosing.
- Plasma donation within 7 days prior to the first dosing.
- Has participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Data sourced from ClinicalTrials.gov (NCT05064449). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.